ABSTRACT
The conventional treatment of staphylococcal endocarditis requires in-patient administration, is inconvenient, and is potentially toxic. Increasing experience with well-absorbed, well-tolerated and highly active agents such as the new quinolones has prompted interest in their use as therapeutic alternatives for the treatment of such infections. We describe a case of staphylococcal endocarditis which failed to respond to conventional therapy, but where the addition of moxifloxacin, an 8-methoxyquinolone, was curative.
Subject(s)
Anti-Infective Agents/therapeutic use , Aza Compounds , Endocarditis, Bacterial/drug therapy , Fluoroquinolones , Quinolines , Staphylococcus aureus/isolation & purification , Adult , Endocarditis, Bacterial/microbiology , Humans , Male , Moxifloxacin , Staphylococcal Infections/drug therapySubject(s)
Anti-Bacterial Agents/therapeutic use , Clindamycin/therapeutic use , Erythromycin/therapeutic use , Macrolides , Staphylococcal Infections/drug therapy , Anti-Bacterial Agents/pharmacology , Drug Resistance, Microbial , Humans , Lincosamides , Microbial Sensitivity Tests , Virginiamycin/pharmacologyABSTRACT
A randomized double-blind controlled trial of the effect of vitamin D supplementation on the abilities of elderly hospital patients to carry out basic activities of daily life is described. Those patients included in the trial had plasma 25-hydroxyvitamin D concentrations which were low or low normal as judged by the normal range in young adults. After 2 to 9 months on the trial there was no significant difference in the performance of the control and treatment groups.